Innovative Ultrasound Technology in Neuromuscular Disease

Beth Israel Deaconess Medical Center223 enrolled

Overview

This study is utilizing ultrasound measurement to measure neuromuscular disease status in adult patients. The hypothesis is the by quantifying ultrasound data, it is possible that ultrasound can be utilized as a tool to determine if a disease is responding to therapy or progressing.

Study Type

OBSERVATIONAL

Enrollment

223

Conditions

Amyotrophic Lateral Sclerosis Muscular Dystrophy Radiculopathy Myopathy Polyneuropathy and Mononeuropathies Trauma Injury Orthopedic Disorder

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * History of a well-defined, localized or generalized neuromuscular condition producing weakness or muscle atrophy, including disuse atrophy. Exclusion Criteria: * Multiple generalized neuromuscular conditions.

Locations (1)

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Quantitative ultrasound data, including quantified grayscale data and backscattered acoustic data

Ultrasound data will be collected on multiple muscles in each person. The images will then be quantified using either 1. A grayscale technique in which the images themselves are analyzed via standard image software (e.g., Adobe Photoshop) as to level of echo intensity in a pre-specific region of interest or 2. the raw quantified backscatter data is captured by the transducer, expressed as a unit of power, in the same pre-specified area of interest

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.